Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:37:48 2024-05-31 am EDT 5-day change 1st Jan Change
89.76 EUR +1.34% Intraday chart for Sanofi +0.27% -.--%
Sales 2024 * 46.56B 50.49B Sales 2025 * 49.84B 54.05B Capitalization 112B 122B
Net income 2024 * 7.05B 7.65B Net income 2025 * 8.77B 9.51B EV / Sales 2024 * 2.55 x
Net Debt 2024 * 6.69B 7.25B Net Debt 2025 * 2.29B 2.49B EV / Sales 2025 * 2.3 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
12.8 x
Employees 86,088
Yield 2024 *
4.31%
Yield 2025 *
4.55%
Free-Float 87.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.34%
1 week+0.27%
1 month-3.57%
3 months+2.81%
6 months+4.64%
More quotes
1 week
87.04
Extreme 87.04
90.07
1 month
87.04
Extreme 87.04
94.47
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-05-31 89.76 +1.34% 3,945,635
24-05-30 88.57 +0.98% 850,720
24-05-29 87.71 -0.98% 1,193,241
24-05-28 88.58 -1.42% 961,541
24-05-27 89.86 +0.38% 500,305

Real-time Euronext Paris, May 31, 2024 at 11:37 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.76 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.53%
Consensus